|
THNSL1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.71716024416946E-13 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.43418610321078E-12 |
| Normal-vs-Stage2 |
5.21629999972184E-07 |
| Normal-vs-Stage3 |
4.87387907810444E-14 |
| Normal-vs-Stage4 |
1.11022302462516E-15 |
| Stage1-vs-Stage2 |
5.045400E-04 |
| Stage1-vs-Stage3 |
6.279800E-02 |
| Stage1-vs-Stage4 |
8.225400E-04 |
| Stage2-vs-Stage3 |
7.50870000000292E-05 |
| Stage2-vs-Stage4 |
4.08829999964944E-07 |
| Stage3-vs-Stage4 |
1.692040E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.73505654288419E-12 |
| Normal-vs-AfricanAmerican |
4.17560000021133E-07 |
| Normal-vs-Asian |
1.59260382659454E-11 |
| Caucasian-vs-AfricanAmerican |
3.972400E-01 |
| Caucasian-vs-Asian |
2.769800E-01 |
| AfricanAmerican-vs-Asian |
9.627400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.29283259045587E-12 |
| Normal-vs-Female |
9.98867655255253E-13 |
| Male-vs-Female |
6.846200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.1227464230833E-13 |
| Normal-vs-Age(41-60Yrs) |
2.84605672362659E-12 |
| Normal-vs-Age(61-80Yrs) |
1.91530125093209E-11 |
| Normal-vs-Age(81-100Yrs) |
2.989500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.069000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.472570E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.946600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.871200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.409400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.831200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.22689999998627E-06 |
| Classical-VS-Follicular |
3.53169999911529E-08 |
| Classical-VS-Other |
7.118200E-01 |
| Classical-VS-Normal |
2.14417372745856E-12 |
| Tall-VS-Follicular |
1.86295423532101E-13 |
| Tall-VS-Other |
1.996640E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
1.869420E-01 |
| Follicular-VS-Normal |
1.55339999974302E-07 |
| Other-VS-Normal |
2.576100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.95899962918133E-11 |
| Normal-vs-N1 |
4.44089209850063E-16 |
| N0-vs-N1 |
4.11619999995949E-06 |
|
|
